Małgorzata Drozd

Małgorzata Drozd

Auto-generated profile, based on publicly available information

Małgorzata Drozd

Independent Public Clinical Hospital No. 4 in Lublin, Jaczewskiego 8, 20-954 Lublin

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
PMPaweł Marzęda
Paweł Marzęda
PWPaula Wróblewska-Łuczka
Paula Wróblewska-Łuczka
MDMałgorzata Drozd
Małgorzata Drozd
MFMagdalena Florek-Łuszczki
Magdalena Florek-Łuszczki
KZKatarzyna Załuska-Ogryzek
Katarzyna Załuska-Ogryzek
JŁJarogniew J. Łuszczki
Jarogniew J. Łuszczki
The medical application of cannabidiol (CBD) has been gathering increasing attention in recent years. This non-psychotropic cannabis-derived compound possesses antiepileptic, antipsychotic, anti-inflammatory and anxiolytic properties. Recent studies report that it also exerts antineoplastic effects in multiple types of cancers, including melanoma. In this in vitro study we tried to reveal the anticancer properties of CBD in malignant melanoma cell lines (SK-MEL 28, A375, FM55P and FM55M2) administered alone, as well as in combination with mitoxantrone (MTX) or cisplatin (CDDP). The effects of CBD on the viability of melanoma cells were measured by the MTT assay; cytotoxicity was determined in the LDH test and proliferation in the BrdU test. Moreover, the safety of CBD was tested in human keratinocytes (HaCaT) in LDH and MTT tests. Results indicate that CBD reduces the viability and proliferation of melanoma-malignant cells and exerts additive interactions with MTX. Unfortunately, CBD produced antagonistic interaction when combined with CDDP. CBD does not cause significant cytotoxicity in HaCaT cell line. In conclusion, CBD may be considered as a part of melanoma multi-drug therapy when combined with MTX. A special attention should be paid to the combination of CBD with CDDP due to the antagonistic interaction observed in the studied malignant melanoma cell lines.

15 July 2021 in Pharmacological Reports
Verified
Journal Article
Open access
PDF file
PMPaweł Marzęda
Paweł Marzęda
MDMałgorzata Drozd
Małgorzata Drozd
PWPaula Wróblewska-Łuczka
Paula Wróblewska-Łuczka
JŁJarogniew J. Łuszczki
Jarogniew J. Łuszczki
Melanoma is one of the most aggressive malignances in human. Recently developed therapies improved overall survival rate, however, the treatment of melanoma still remains a challenging issue. This review attempts to summarize recent advances in studies on cannabinoids used in the setting of melanoma treatment. Searches were carried out in PubMed, Google Scholar, Scopus, Research Gate. Conclusions after analysis of available data suggest that cannabinoids limit number of metastasis, and reduce growth of melanoma. The findings indicate that cannabinoids induce apoptosis, necrosis, autophagy, cell cycle arrest and exert significant interactions with tumor microenvironment. Cannabinoids should be rather considered as a part of multi-targeted anti-tumor therapy instead of being standalone agent. Moreover, cannabinoids are likely to improve quality of life in patients with cancer, due to different supportive effects, like analgesia and/or anti-emetic effects. In this review, it was pointed out that cannabinoids may be potentially useful in the melanoma therapy. Nevertheless, due to limited amount of data, great variety of cannabinoids available and lack of clinical trials, further studies are required to determine an exact role of cannabinoids in the treatment of melanoma. Graphic

1 September 2020 in Journal of Education, Health and Sport
Verified
Journal Article
Closed access
PDF file
MDMałgorzata Drozd
Małgorzata Drozd
MMMagdalena Marzęda
Magdalena Marzęda
ABAgnieszka Blicharz
Agnieszka Blicharz
JCJakub Czarnota
Jakub Czarnota
HPHalina Piecewicz-Szczęsna
Halina Piecewicz-Szczęsna
Introduction and purpose: Fibromyalgia is a chronic condition affecting almost 2% of the general population, mostly women. The main symptoms are chronic diffuse musculoskeletal pain or stiffness, tiredness, nonrestorative sleep, anxiety, depression and cognitive dysfunction. The etiology of fibromyalgia remains unclear and has been the subject of debate and scientific investigation. The aim of this article was to collect and analyse current and new information on the etiology of fibromyalgia and present the most popular hypotheses.Brief description of the state of knowledge: Pathogenesis of fibromyalgia is multifactorial. Genetic factors, in addition to environmental factors, such as psychical stress and various types of infection, are considered to be the triggers of the disease. Central sensitization became a commonly accepted hypothesis of the fibromyalgia’s pathogenesis. However, the newest finding of small fiber neuropathy in patients with fibromyalgia supports another hypothesis, in which the disease is presented as stress-related dysautonomia with neuropathic pain features.Conclusions: Understanding the pathogenesis of fibromyalgia is essential to provide the best care to the patients with fibromyalgia. Although there are multiple evidence for central sensitization hypothesis, new findings continue to emerge and question commonly accepted paradigm. Despite numerous findings on etiology of fibromyalgia, more studies are needed.

Verified
Journal Article
Open access
PDF file
PMPaweł Marzęda
Paweł Marzęda
PWPaula Wróblewska-Łuczka
Paula Wróblewska-Łuczka
MFMagdalena Florek-Łuszczki
Magdalena Florek-Łuszczki
MDMałgorzata Drozd
Małgorzata Drozd
AGAgnieszka Góralczyk
Agnieszka Góralczyk
JŁJarogniew J. Łuszczki
Jarogniew J. Łuszczki
Due to the unique structures of arvanil and olvanil, the drugs combine certain properties of both cannabinoids and vanilloids, which makes them able to stimulate both TPRV1 and CB1 receptors and causes them to be interesting agents in the setting of carcinoma treatment. The aim of this study was to investigate the cytotoxic and anti-proliferative effects of arvanil and olvanil when administered alone and in combination with cisplatin (CDDP) and mitoxantrone (MTX), using various primary (A375, FM55P) and metastatic (SK–MEL 28, FM55M2) human malignant melanoma cell lines. The results indicate that both arvanil and olvanil inhibited (dose-dependently) the viability and proliferation of various malignant melanoma cells, as demonstrated by MTT and BrdU assays. The safety profile of both arvanil and olvanil tested in human keratinocytes (HaCaT) and normal human melanocytes (HEMa–LP) revealed that neither arvanil nor olvanil caused significant cytotoxicity in HaCaT and HEMa–LP cell lines in LDH and MTT assays. Isobolographically, it was found that both arvanil and olvanil exerted additive interactions with MTX and antagonistic interactions with CDDP in the studied malignant melanoma cell lines. In conclusion, the combinations of arvanil or olvanil with MTX may be considered as a part of melanoma multi-drug therapy; however, the combination of these compounds with CDDP should be carefully considered due to the antagonistic interactions observed in the studied malignant melanoma cell lines.

25 May 2022 in Journal of Education, Health and Sport
Verified
Journal Article
Open access
PDF file
MDMałgorzata Drozd
Małgorzata Drozd
PMPaweł Marzęda
Paweł Marzęda
JCJakub Czarnota
Jakub Czarnota
Michał DobrzyńskiMichał Dobrzyński
Michał Dobrzyński
TSTomasz Skubel
Tomasz Skubel
NRNatalia Rybak
Natalia Rybak
Introduction: Lung cancer is the number-one cause of death due to neoplasms worldwide. The 5-year overall survival rate is only 22%. In advanced stages, the therapeutic options are limited to chemotherapy, radiotherapy, molecularly targeted therapy and immunotherapy. Phytocannabinoids, the components of Cannabis sativa, their synthetic derivatives and endogenous cannabinoids have demonstrated anticancer activity in various common cancers - breast, prostate, colorectal and lung cancers, among others. The aim of this review was to assess the potential value of cannabinoids in the treatment of lung cancer. State of knowledge: The majority of preclinical studies demonstrates that cannabinoids inhibit lung cancer cell viability both in vitro and in vivo. The main mechanism of anticancer activity is the induction of apoptosis, triggered by activation of CB1, CB2 and TRPV1 receptors or independently via other pathways. Cannabinoids influence the components of the tumour microenvironment - cancer associated fibroblasts, macrophages and lymphokine-activated-killer cells. Cannabinoids alter leukocyte infiltration into anti-cancer proportions, inhibit expression of EGFR and PAI-1 and increase the expression of TIMP-1. As a result they induce cytotoxicity, decrease proliferation, migration and invasive potential of lung cancer cells, suppress angiogenesis and metastasis forming. Patients with advanced lung cancer may also benefit from analgesic, antiemetic and appetite improving properties of cannabinoids. Summary: Cannabinoids can be a supplementary agent in systemic anticancer therapeutic regimen in the future. The exact mechanisms of action, specific doses in anticancer treatment, routes of administration and interactions with other anticancer drugs has yet to be determined. Thus the clinical studies on cannabinoids in lung cancer should be performed in the future.

1 September 2020 in Journal of Education, Health and Sport
Verified
Journal Article
Closed access
PDF file
ABAgnieszka Blicharz
Agnieszka Blicharz
MMMagdalena Marzęda
Magdalena Marzęda
MDMałgorzara Drozd
Małgorzara Drozd
JCJakub Czarnota
Jakub Czarnota
HPHalina Piecewicz-Szczęsna
Halina Piecewicz-Szczęsna
Introduction and purpose: Thiamin (Vitamin B1) is a water-soluble vitamin. It plays an important role in many biological processes, mainly in glucose metabolism. Its deficiency is called beriberi disease. Beriberi was discovered at the turn of the 19th and 20th centuries and is now a disease that occurs in both underdeveloped and highly developed countries.Brief description of the state of knowledge: Thiamine deficiency can affect the cardiovascular, nervous and immune systems, which is seen as dry, wet, fulminant beriberi or as Wernicke-Korsakoff syndrome. Worldwide, vitamin B1 deficiency is most commonly reported in populations where rice and ground grains are the main food source, but also in patients with chronic alcohol abuse, diabetes, gastrointestinal surgery, cancer, and patients undergoing chronic diuretic therapy, which increases urine loss.Summary: Treatment of beriberi disease consists in supplementing vitamin B1 in appropriate doses. The symptoms of thiamine deficiency are non-specific, however, early diagnosis and initiation of vitamin administration quickly lead to clinical improvement. It should be remembered that thiamine deficiency is often not included in the differential diagnosis of complaints reported by patients. This may be due to the belief that diets in European countries containing food products enriched with vitamins exclude clinically evident micronutrient deficiencies.